Assenagon Asset Management
CORT icon

Assenagon Asset Management’s Corcept Therapeutics CORT Stock Holding History

Assenagon Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-349,667
Closed -$6.09M – 1057
2020
Q3 		$6.09M Buy
+349,667
New +$5.57M 0.03% 285
2020
Q2 		– Sell
-148,685
Closed -$1.77M – 1131
2020
Q1 		$1.77M Buy
+148,685
New +$1.84M 0.01% 382

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Assenagon Asset Management's CORT Position: Q4 2020 in Review

Assenagon Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2020, closing a stake of 349,667 shares — an estimated $6.09M sold.

Assenagon Asset Management first reported a position in CORT in Q1 2020 and held it in 2 quarters. The position peaked at $6.09M in Q3 2020. 226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

  • Assenagon Asset Management reported no remaining Corcept Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Assenagon Asset Management sold 349,667 Corcept Therapeutics shares in Q4 2020, an estimated $6.09M.
  • Assenagon Asset Management first reported a position in Corcept Therapeutics in Q1 2020 and held it in 2 quarters.
  • Assenagon Asset Management's Corcept Therapeutics position peaked at $6.09M in Q3 2020.
  • 226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Assenagon Asset Management's 13F filing for Q4 2020, filed 1 Feb 2021.